Shared on 27 Aug 25

Fair value Decreased 3.71%

Analysts have revised Carl Zeiss Meditec's price target downward to €53.61, citing weaker-than-expected earnings, intensified competition and pricing pressures in ophthalmology, subdued recovery in elective procedures, margin compression, and persistent macroeconomic and FX headwinds. Analyst Commentary Bearish analysts are reacting to disappointing recent earnings performance, which has lagged behind expectations.

Read more

0 votesShare

Shared on 11 Aug 25

Fair value Decreased 8.63%

The downward revision of Carl Zeiss Meditec’s consensus price target primarily reflects reduced revenue growth forecasts, with fair value lowered from €60.93 to €56.87 per share. What's in the News ZEISS Medical Technology’s CLARUS 700 received NMPA approval in China, enhancing advanced retinal diagnostics with ultra-widefield, high-resolution imaging.

Read more

0 votesShare

Shared on 01 May 25

Fair value Decreased 4.67%

Read more

0 votesShare

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

Fair value Increased 1.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 4.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 26 Mar 25

Fair value Increased 1.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 12 Mar 25

Fair value Decreased 5.48%

AnalystConsensusTarget has decreased future PE multiple from 24.0x to 20.3x.

Read more

0 votesShare